Mineralys TherapeuticsMLYS
Recorded

Mineralys Therapeutics 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration39 minParticipants14

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Please note, this conference is being recorded. It is now my pleasure to introduce your host, Dan Ferry of LifeSci Advisors. Please go ahead, sir. Thank you.

Dan FerryManaging Director

I would like to welcome everyone joining us today for our third quarter 2026 conference call. This afternoon, after the close of market trading, we issued a press release providing our third quarter 2026 financial results and business updates. A replay of today's call will be available on the Investors section of our website approximately one hour after its completion. After our prepared remarks, we will open the call for Q&A. Before we begin, I would like to remind everyone that this conference call webcast will contain forward-looking statements about the company. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in today's press release and our SEC filings, including our annual report on Form 10-K and subsequent filings.

Dan FerryManaging Director

Please note that these forward-looking statements reflect our opinions only as of today, November 4, 2026. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. I would now like to turn the call over to Jon Congleton, Chief Executive Officer of Mineralys Therapeutics.

Jon CongletonCEO

Thank you, Dan. Good afternoon, everyone, and welcome to our third quarter 2026 financial results and corporate update conference call. We've had an exciting and productive quarter, and I look forward to sharing our updates. Today, I'm joined by Adam Levy, our Chief Financial Officer, and Eric Warren, our Chief Commercial Officer. I'll begin with an overview of the business and our recent clinical progress. Eric will then provide a commercial update, and Adam will review our third quarter financial results before we open the call for your questions. We are now just weeks away from our PDUFA target date of December 22. While the FDA continues its review of the NDA, our focus is on completing our launch preparations so that we are ready to reach patients soon after the potential approval of lorundrostat.

Jon CongletonCEO

Approximately 20 million adults with hypertension treated with two or more drugs fail to achieve their blood pressure goal. The implications are clear. If people with hypertension can achieve their blood pressure goals, they are less likely to have poor outcomes that impact their quality of life and longevity. Providing innovations to help people achieve their blood pressure goals is what drives our work every day. A critical part of that work is the publication and presentation of lorundrostat data for the medical community to build awareness, understanding, and enthusiasm for its clinical profile. The major medical meetings this fall are giving us a series of opportunities to present data on lorundrostat that highlight its differentiated profile. We recently presented new data at the AHA Hypertension Scientific Sessions and at ASN Kidney Week, and we have an important late-breaking presentation coming this Sunday at the American Heart Association Scientific Sessions.

Jon CongletonCEO

We believe the data we have presented to date add to the strength of the data from our clinical program and suggest the potential of lorundrostat to help patients with difficult-to-treat hypertension reach their guideline-recommended systolic blood pressure goals. These data include a new analysis of our pivotal phase III LAUNCH-HTN trial. Participants in LAUNCH-HTN had uncontrolled or treatment-resistant hypertension despite being treated with two to five antihypertensive therapies. In this 12-week analysis, 46% of participants treated with lorundrostat 50 milligrams achieved the AHA/ACC guideline-recommended office systolic blood pressure target of less than 130 millimeters of mercury, and more than two-thirds achieved a systolic blood pressure reduction of at least 10 millimeters of mercury. We believe these are compelling data in a population that had previously not been able to reach their goal with existing therapies.

Jon CongletonCEO

We also presented the final results from our phase II EXPLORE-OSA trial in overweight or obese adults with moderate to severe obstructive sleep apnea and hypertension. As many as 70%-80% of adults with resistant hypertension have OSA. Their nighttime blood pressure is often elevated and is considered a significant driver of cardiovascular risk. In EXPLORE-OSA, lorundrostat 50 milligrams taken once daily in the evening reduced morning systolic blood pressure by 11.1 millimeters of mercury at week four compared with a 1.0 millimeter mercury reduction with placebo. Although we did not observe a measurable change in the apnea-hypopnea index, the blood pressure reduction was consistent with what we saw in our pivotal trials, and the safety and tolerability profile was favorable, with no evidence of serious safety events, including hyperkalemia.

Jon CongletonCEO

We believe these results further emphasize the potential of lorundrostat in a high-risk subpopulation in whom blood pressure is particularly difficult to control. New long-term efficacy and safety data from our ongoing TRANSFORM-HTN open-label extension trial will be featured in a late-breaking scientific presentation at the American Heart Association Scientific Sessions 2026 on November 8th in Chicago. Durable blood pressure control and a well-characterized long-term safety profile are important considerations for physicians managing a chronic condition like hypertension. We look forward to sharing these data with the medical community. As we have discussed, aldosterone plays a central role in hypertension, as well as other cardiorenal and metabolic disorders. We remain committed to advancing our work in aldosterone-driven disease states and are evaluating the next steps in the clinical development of lorundrostat. Once we have finalized those plans, we will share them with you.

Jon CongletonCEO

We're also excited to have two new board members join Mineralys as we prepare for the launch of lorundrostat. Chris Peterson and Lonnel Coats are two experienced executives that bring a wealth of commercial expertise to Mineralys at this juncture of our corporate life. They will be providing their insights, perspective, and experience to our management team as we prepare the market, the asset, and the company for commercialization. As a part of this transition, Derek DiRocco, who joined the board while we were a private company, will be concluding his tenure at the end of this year. I want to thank Derek for his support and guidance over the past several years during our development stage. With that, I'll turn the call over to Eric to provide a commercial update.

Eric WarrenChief Commercial Officer

Thank you, John. Our commercial organization continues to execute against our launch preparation plans, and we are advancing through the final stages of launch readiness. We believe we are well-positioned to support awareness, drive adoption, and create favorable access soon after potential approval. Let me begin with the opportunity. As John noted, approximately 20 million adults in the U.S. are living with uncontrolled or resistant hypertension, representing a large and underserved population with meaningful clinical need. Our commercial focus is on clearly communicating the potential value of lorundrostat for appropriate patients relative to existing treatment options, including its potential to improve blood pressure control, help more patients reach treatment goals, and to do so with a safety profile supported by our clinical data package. From an execution standpoint, I am pleased to report that our field sales team is now in place.

Eric WarrenChief Commercial Officer

In addition to our seasoned commercial leadership team, we have hired sales representatives with an average industry tenure of approximately 15 years. We have also continued to strengthen our medical affairs and medical science liaison capabilities. As John mentioned, our engagement with leading hypertension experts remains active, with a focus on education around the unmet need in uncontrolled or resistant hypertension. On the market access front, our engagement with payers now extends to the majority of U.S. covered lives. Our discussions continue to center on the clinical and economic burden of uncontrolled hypertension and the value proposition supported by lorundrostat's clinical data package. These conversations continue to reinforce our view that payers recognize the unmet need in this patient population. In parallel, we are finalizing a full-service patient support program designed to help physicians, their office staff, and patients navigate access efficiently.

Eric WarrenChief Commercial Officer

Our brand marketing efforts are also well underway, building the launch campaign we described last quarter, which is designed to educate both healthcare providers and patients. Taken together, we believe these efforts reflect launch readiness across the organization. We have built the team, advanced payer and provider engagement, expanded our educational infrastructure, and put the core launch capabilities in place to support the introduction of lorundrostat, if approved. We remain encouraged by feedback we are receiving from physicians, payers, and patients, and we believe Mineralys is well-positioned for launch. With that, I'll turn the call over to Adam to review our third quarter financial results.

Adam LevyCFO

Thank you, Eric. Good afternoon, everyone. Today, I will discuss select portions of our third quarter 2026 financial results. Additional details can be found in our Form 10-Q, which will be filed with the SEC today. We ended the quarter with cash equivalents, and investments of $624.7 million as of September 30, 2026, compared to $656.6 million as of December 31, 2025. We believe that our current cash equivalents, and investments will be sufficient to fund our planned operations, including the commercial launch of lorundrostat, into 2028. R&D expenses for the quarter ended September 30, 2026, were $22.7 million, compared to $31.5 million for the quarter ended September 30, 2025.

Adam LevyCFO

The decrease in R&D expenses was primarily due to $8.5 million of lower preclinical and clinical costs resulting from the conclusion of the lorundrostat pivotal program in the second quarter of 2025, and $0.3 million of decreased clinical supply, manufacturing, regulatory, and other costs. G&A expenses were $37.4 million for the quarter ended September 30, 2026, compared to $9.7 million for the quarter ended September 30, 2025. The increase in G&A expenses was primarily due to investments to expand our operations in preparation for commercialization, including $15.4 million of higher professional fees, $11.4 million of increased personnel-related expenses resulting from headcount growth and increased compensation, and $0.9 million of increased other administrative expenses. Total other income net was $2.8 million for the quarter ended September 30, 2026, compared to $4.2 million for the quarter ended September 30, 2025.

Adam LevyCFO

The decrease was primarily due to $3.2 million of increased interest expense related to the senior secured term loan entered into in June 2026, partially offset by $1.8 million of increased interest earned on investments as a result of higher average cash balances. Net loss was $57.3 million for the quarter ended September 30, 2026, compared to $36.9 million for the quarter ended September 30, 2025. The increase was primarily attributable to the factors impacting our expenses that I described earlier. With that, I will ask the operator to open the call for questions.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day